Based on the previous findings, which demonstrated that knockdown of PARP1 or inhibition of PARP1 using olaparib results in the upregulation of BLM activity, mRNA abundance, and protein levels, we hypothesized that the inhibition of BLM by ML216 could enhance the anti-tumor effectiveness of olaparib against PCa. This evidence concerns the gene PARP1 and neoplasm.